A Short Update on the Use of Monoclonal Antibodies in COVID-19.

Publication date: Mar 05, 2024

Monoclonal antibodies in the prophylaxis and treatment of COVID-19 have been crucial in reducing severe infections when vaccines were unavailable. However, as the virus and its variants have changed over time, the effectiveness of monoclonal antibodies has been questioned. This technical note highlights the need to assess the antiviral activity of these antibodies against new variants and adapt treatment strategies accordingly. On the one hand, in vitro studies have suggested reduced susceptibility of the latest variants to monoclonal antibodies, whereas clinical data still show benefits in reducing severe illness and mortality, indicating that laboratory results do not always mirror real-world outcomes. As a result, although resistance to monoclonal antibodies can develop over time, they could still have an important role in COVID-19 treatment, especially when used in combination, and ongoing research aims to identify effective antibodies against new variants.

Concepts Keywords
Covid clinical data
Illness COVID-19
Laboratory monoclonal antibodies
Short resistance
Vaccines variants


Type Source Name
disease MESH COVID-19
disease MESH infections
disease VO time
disease VO effectiveness
disease IDO susceptibility
disease VO effective

Original Article

(Visited 1 times, 1 visits today)